BACKGROUND: Case studies have suggested the efficacy of catheter-free, electrophysiology-guided noninvasive cardiac radioablation for ventricular tachycardia (VT) using stereotactic body radiation therapy, although prospective data are lacking.
V entricular tachycardia (VT) is a life-threatening heart rhythm disorder that is often caused by electric reentry within and around patches of heterogeneous myocardial fibrosis. 1 Invasive catheter procedures to treat VT first identify the circuits within the fibrosis and then deliver thermal-ablative energy to these regions. 2 Stereotactic body radiotherapy (SBRT) is a technique that delivers precise, high doses of radiation to targets in the body with reduced exposure to adjacent normal tissue. 3 When used to treat tumors, SBRT can achieve high rates of tumor control and minimal toxicity, including tumors adjacent to the heart. 4, 5 SBRT has the potential to treat VT by delivering ablative energy noninvasively, minimizing procedural risk for the patient. 6 Preclinical studies exploring SBRT using various forms of particle therapy (photons, protons, carbon) for cardiac ablation have demonstrated histological changes and electrophysiological effects without acute or subacute adverse effects over 6-month follow-up. [7] [8] [9] Choosing the precise location to target for ablation, while avoiding healthy tissue and surrounding thoracic structures, requires a synthesis of anatomic and electric information. A pilot case series used cardiac magnetic resonance imaging, cardiac single-photon emission computed tomography, 12-lead ECG during VT, and electrocardiographic imaging (ECGI) to guide cardiac SBRT. 10 The result demonstrated a strong antiarrhythmic effect that controlled VT storm and allowed reduction of antiarrhythmic medication. Other case reports have yielded generally positive short-term results without report of significant complications. [11] [12] [13] Although late toxic effects of radiotherapy to the heart have been reported in the treatment of thoracic tumors, late toxicity from high-dose SBRT applied to focal areas of a previously injured heart is unknown. 14, 15 Formal prospective evaluation of short-term risk, late toxicities, and antiarrhythmic effects of noninvasive cardiac radioablation has not been completed. Here we describe the results of a prospective trial of noninvasive cardiac radioablation for the control of treatmentrefractory VT.
METHODS
The data, analytical methods, and study materials will be made available at Washington University Open Scholarship (https://openscholarship.wustl.edu/) 12 months after analysis of the primary end points.
Trial Design
The ENCORE-VT trial (Electrophysiology-Guided Noninvasive Cardiac Radioablation for Ventricular Tachycardia) was a prospective single-arm phase I/II trial conducted at a single center. The local institutional review board approved the study without Investigational Device Exemption based on interpretation of the indications for use and risk of linear accelerators and electrocardiographic imaging technology. All participants provided informed consent, and an independent Data and Safety Monitoring Committee reviewed data semiannually and provided guidance on study continuation. Subsequent to study enrollment, the US Food and Drug Administration reviewed the protocol and categorized the research as a significant risk study, which requires Investigational Device Exemption approval. Although the US Food and Drug Administration did not approve the protocol, analysis plan, or data, the investigators, institutional review board, and US Food and Drug Administration worked together to ensure that the appropriate human subject protections were in place.
Patients
Eligible patients were ≥18 years of age and had ≥3 episodes of sustained monomorphic VT or cardiomyopathy (left ventricular ejection fraction <50%) related to monomorphic premature ventricular contractions (PVCs; >20%) and required failure of ≥1 antiarrhythmic medication and ≥1 catheter ablation (or had a contraindication to catheter ablation). Patients could not have received past radiotherapy to the anticipated treatment field. Patients were deemed ineligible if they had heart failure dependent on inotropes or a left-ventricular assist device or were deemed unlikely to live 12 months in the absence of VT. Patients were also ineligible if they had polymorphic VT or ventricular fibrillation, >3 distinct clinical VT morphologies, or >5 induced VT morphologies during noninvasive-programmed stimulation testing. 
Intervention

Treatment and Follow-up
Patients received a single dose of 25 Gy delivered with SBRT to the arrhythmogenic target as defined earlier. The general method for SBRT planning and delivery has been previously described. 10 Full study-specific details regarding the SBRT procedure, including simulation, treatment planning, and delivery, are available in the online-only Data Supplement. After completion of treatment, a prespecified implantable cardioverter defibrillator (ICD) programming plan was implemented for all patients, which included a zone for detection ≥20 ms slower than the slowest clinical or induced VT. ICDs were remotely monitored as part of clinical care. If not contraindicated, oral anticoagulation was prescribed during the first month after treatment. Study visits occurred at day 3; at 2, 4, and 6 weeks; at 6 and 12 months; and annually thereafter. Adverse events were continuously assessed, and ICD interrogation was performed at each study visit. A 12-lead ECG was obtained at day 3, at 6 weeks, and at 3, 6, and 12 months. For patients with PVCs, a 24-hour Holter monitor was performed at week 6 and at months 3, 6, and 12. A chest computed tomography scan was performed along with ECGI (without noninvasive-programmed stimulation) at 3 and 12 months.
Outcome Measures and Statistical Analysis
The ENCORE-VT trial was designed with the coprimary end points of safety and efficacy. The primary safety end point was defined as the rate of ≤90-day serious adverse events (SAEs) defined using Common Terminology Criteria for Adverse Events (version 4.0) criteria that were treatment-related (possibly, probably, or definitely related to study treatment). SAEs were defined as any grade 3 toxicity requiring hospitalization or any grade 4 to 5 toxicity. An early stopping rule was set to halt protocol enrollment if ≥5 of the first 10 patients developed an SAE.
The primary efficacy end point was defined as the number of subjects with any reduction in number of ICD treatments for VT or 24-hour PVC burden comparing the 6-month period before and after SBRT, with a 6-week blanking period after treatment to allow for a treatment effect. ICD treatments are composed of ICD shocks and antitachycardia pacing. Additional select prespecified secondary objectives reported herein include stricter efficacy end points (50% reduction, 95% reduction), a patient-derived end point (reduction in shocks for patients with VT, improvement in cardiac function for PVCs), overall survival, late (>90 days to 1 year) adverse events, and quality of life as measured by the Short Form-36 questionnaire.
The study was powered as a balance between ensuring a high likelihood of safety with a preliminary assessment of efficacy. Considering that all patients had failed previous treatments to halt VT, the population in this study was expected to be at higher risk, and an assumption was made that SAE rates ≤20% and efficacy as low as 40% would be clinically acceptable. Using a 1-sided 1-sample test for proportions, 19 patients provided 75.4% power to determine that the SAE rate was not truly >20% (range, 5-20; α=0.0829) and 81.5% power to determine that efficacy was not <40% (range, 40-65; α=0.0885).
Continuous variables are reported as the median and range. The Wilcoxon signed-rank test was used to compare the number of VT events, ICD shocks, and antitachycardia pacing events between the baseline and 6-month time points. McNemar paired testing was used to assess changes in the proportions of antiarrhythmic use. For quality-of-life analysis, mean values in each of the Short Form-36 measures at baseline, 6 weeks, and 6 months were compared using a repeatedmeasures ANOVA with Greenhouse-Geisser correction. Median follow-up was calculated from the date of treatment to the date of last scheduled follow-up or death. Kaplan-Meier analysis was used to estimate the survival function. All statistics were performed in IBM SPSS Statistics for Windows (version 24.0). Table 1 outlines the demographic data for the cohort, which was characterized by median age 66 years, 89.5% male (n=17), ischemic cardiomyopathy (n=11, 57.9%), median left ventricular ejection fraction 25% (range, 15-58), and New York Heart Association class III/IV (73.7%). The median number of previous catheter ablations before enrollment was 1 (range, 0-4). Three patients did not have prior catheter ablation because of mechanical aortic valve replacement and mitral valve replacement (n=1), severely reduced left ventricle ejection fraction with medical comorbidities precluding hemodynamic support (n=1), and presence of mobile left ventricle thrombus (n=1). Median follow-up was 13 months, and no patients were lost to follow-up.
RESULTS
Patients and Treatment
Patients were enrolled for either ICD-treated VT (n=17) or PVC-related cardiomyopathy (n=2). Of the 17 patients with ICD-treated VT, 10 were considered VT storm (≥3 VT episodes in 24 hours), and 2 were in sustained VT at the time of treatment. More than half (n=11, 57.9%) of the patients were on >1 antiarrhythmic drug and taking ≥300 mg of amiodarone daily at the time of treatment.
Targeting and treatment characteristics are reported in Table 2 . Ten patients were excluded from cardiac magnetic resonance imaging primarily because of abandoned ICD leads. All patients underwent chest CT, nuclear imaging, and induction of VT with subsequent 12-lead ECG and ECGI images. Patients had a median of 2 VTs induced (range, 1-5).
Median gross target volume was 25.4 cc (range, 6.4-88.6). The patients with PVC had the smallest gross target volume (6.4 cc, 11.5 cc 
Safety
No acute toxicity was observed during or immediately after SBRT. No adverse effects were observed with ICDs during or after SBRT. A list of all ≤90-day SAEs is shown in Table 3 . Two patients (10.5%) experienced a grade 3 treatment-related (possibly, probably, or definitely related) SAE. One patient was hospitalized 65 days after treatment with a heart failure exacerbation (grade 3) and was conservatively scored as possible. Another patient was hospitalized at 80 days with pericarditis that improved with prednisone and was scored as probable. No grade 4 toxicity was recorded. An additional patient died 17 days after treatment in a nursing home resulting from an accident that was scored as unrelated and did not contribute to the 6-month primary efficacy end point. Early stopping rules were not met, and the Data and Safety Monitoring Committee recommended completion of the study. A complete list of adverse events inclusive of all attributions, grades, and time frames after treatment is shown in Table I in the online-only Data Supplement. Adverse events probably or definitely related to treatment were generally grade 1 to 2 (8 events in 4 patients, 22%). Transient grade 1 fatigue and hypotension were common. Three patients required adjustment of antihypertensive medication because of hypotension in ≤2 weeks of treatment. Other common grade 1 to 2 adverse events included dizziness, dyspnea, and nausea. Two patients (11.1%) developed grade 2 radiation pneumonitis that resolved with steroids. Pericardial effusions were documented 6 times in 5 patients (28%); 3 were asymptomatic, 1 resolved with medical management, and 2 were higher-grade (1 possibly related grade 3, 1 unrelated grade 4 after epicardial access). Patients with symptomatic pericarditis or pneumonitis were treated with prednisone delivered at 1 mg/kg daily (maximum 60 mg), tapered by 10 to 20 mg per week based on symptoms. Six 
Efficacy
Of the 18 patients who survived 6 months, the primary efficacy end point of reduction in VT episodes or PVC burden was achieved in 17/18 (94%) patients. Figure 1 shows the frequency of VT episodes and 24-hour PVC burden before and after noninvasive cardiac radioablation for all 18 patients. For 16 evaluable patients with ICD-treated VT, there were 1778 VT episodes in aggregate in the 6 months before treatment. During the 6-week blanking period, there were 149 episodes. For the next 4.5 months, there were 111 VT episodes (94% total VT episode reduction). The median number of VT episodes decreased from the 6-month preablation period (119; range, 4-292) to the 6-month postablation period (3; range, 0-31; P<0.001). Significant reductions in the median number of ICD shocks (preablation, 4; range, 0-30; postablation, 0; range, 0-7; P=0.002) and for ICD antitachycardia pacing (preablation, 81; range, 0-292; postablation, 3.5; range, 0-29; P=0.001) were observed.
For 2 patients with PVC-related cardiomyopathy, 24-hour PVC burden reduced from 24% to 2% and 26% to 9%, respectively. Left ventricular ejection fraction improved by 13% and 8%, respectively ( Figure IV in the online-only Data Supplement).
Prespecified secondary end points included a 50% reduction and a 95% reduction in VT episodes or 24-hour PVC burden. This end point was achieved in 94% and 61% of patients, respectively. The frequency of VT episodes or PVC burden was reduced by 75% in 89% of patients. A prespecified secondary end point was elimination of ICD shocks or improvement in left ventricular ejection fraction, which was reached in 72% of patients. Although VT burden was reduced in nearly all, many (11/16, 69%) had some recurrence of VT between the end of the 6-week blanking period and 6 months. Overall, survival was 89% at 6 months and 72% at 12 months (Figure 2A ). All-cause mortality is detailed in Table II in the onlineonly Data Supplement. Figure 2B shows the distribution of antiarrhythmic medication use before treatment and at 6 months in 17 evaluable patients. Use of dual antiarrhythmic medications decreased from 59% to 12% (P=0.008). Use of high-dose amiodarone (>300 mg per day) decreased from 47% to 12% (P=0.03). Use of class 1 agents decreased from 59% to 12% (0.008). Three patients stopped antiarrhythmic medication completely.
Selected patient-reported quality of life scores are shown in Figure 2C at baseline, 6 weeks, and 6 months after treatment. Significant improvements were observed in perceived health change and social functioning categories. No changes were observed in general health domain. Overall, significant improvements were observed in 5 of 9 domains, as shown in Figure V and Table II in the online-only Data Supplement. Quality-of-life scores did not decline in any domain. MRI indicates magnetic resonance imaging; LV, left ventricle; SBRT, stereotactic body radiotherapy technique; and VT, ventricular tachycardia.
*Segments refer to inclusion of a location as part of targeting for SBRT. Multiple patients had targets that involved >1 segment, so the total number adds up to >19.
†The target is referred to as the gross target volume (GTV). After outlining the GTV, an additional area around the GTV was added to account for internal motion of the GTV caused by breathing and cardiac motion, as assessed by review of the 4-dimensional CT (4D-CT). This is called the internal target volume (ITV). Finally, an additional safety margin of 5 mm was added to the ITV region for treatment planning to create a planning target volume, which accounts for any residual uncertainties in patient setup, motion, and delivery.
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DISCUSSION
In this prospective phase I/II trial, noninvasive electrophysiology-guided cardiac radioablation was associated with a markedly reduced VT burden with modest short-term risks, reduction in antiarrhythmic drug use, and improvement in quality of life in patients with treatment-refractory VT. The short-term safety of this technique is apparent: there were no acute procedural toxicities, there were no adverse effects to indwelling ICD systems, and there was only 1 probable treatment-related SAE (pericarditis) in ≤90 days that improved with medical management. Patients were treated in the ambulatory setting, with a median treatment time of 15 minutes. This represents a major improvement from current acute procedural risk after invasive catheter ablation (6%-7%). 20, 21 Patients with VT that recurs after a catheter ablation procedure are at 4-to 6-fold increased risk for death. 22 Recurrence of VT in patients with reduced heart function or advanced heart failure symptoms has been associated with a 1-year transplant-free survival rate of 31% to 59%. 23 Although the sample size in this study is small, the 1-year survival of 72% observed with noninvasive cardiac radioablation compares favorably to survival of similar patients.
Specialized cardiac structures (coronary arteries, valves, papillary muscles, and conduction system) may be exposed to radiation based on the anatomical location of the scar. We did not use a fiducial or tracking technique. However, the gain of such a technique for our patients would be expected to be limited given the The first column organizes CTCAE v4.0 adverse events by system and then further divides into specific adverse events. The first row indicates the grade as well as the attribution. No grade 4 events were recorded and are thus not tabulated. Protocol-specific SAEs (SAEs that were possibly, probably, or definitely relative to study treatment) are boldface. CTCAE v4. ORIGINAL RESEARCH ARTICLE modest additional volume of target treated to incorporate motion alone (median 6-cc increase from gross target volume to internal target volume). We did, however, add a conservative additional 5-mm margin to create the final planning target volume based on the remaining uncertainties. The size of ablation volumes necessary to achieve arrhythmia control will likely decrease with improvements in measuring and controlling for complex cardiopulmonary motion during SBRT delivery coupled with refinement of cardiac imaging synthesis and improved understanding of arrhythmic circuits to define the minimum volume for targeting arrhythmias noninvasively. For most patients, the antiarrhythmic effect of cardiac radioablation happened within the first 6 weeks after treatment. This effect occurred well before the expected time course of myocyte cell death mechanisms and replacement fibrosis.
14 Improved understanding of the effect of radiation on diseased cardiac tissues will further improve the safety and efficacy of this technique.
Patient-reported quality-of-life scores were lowest in categories related to physical functioning, fatigue, and general health. It was expected that these symptoms did not improve over the 6 months of follow-up; advanced cardiomyopathies are not expected to recover with this treatment. Highest scores and significant improvement at 6 months were observed in categories associated with social functioning and health-related optimism. This may reflect a patient group regaining confidence after emotionally traumatic storms of VT, ICD shocks, and repeated hospitalizations. 24 Limitations of this study include the nonrandomized nature of the trial, limited long-term follow-up, treat- A, Kaplan-Meier curve of overall survival for all patients. Actuarial overall survival at 6 months was 89% and at 12 months was 72%. B, Stacked bar graph of antiarrhythmic medication usage in patients at baseline and 6 months after treatment. The y axis represents the total number of antiarrhythmic medications used, with the sizes of each color directly proportional to the number of agents used in that particular class of antiarrhythmic medication. Amiodarone usage is split into high-dose (≥300 mg/d) and low-dose (<300 mg/d). Class I agents consisted of mexiletine and flecainide. Class III agents consisted of sotalol. C, Mean scores reported by the 16 patients who were alive at 6 months at baseline, 6 weeks, and 6 months after treatment in 3 selected domains of the Short Form-36 questionnaire: Social Functioning in blue, Health Change in green, and General Health in purple. Asterisks denote a significant change (P<0.05) in mean scores over time. SBRT indicates stereotactic body radiotherapy; SF-36, Short Form-36; QoL, quality of life; and VT, ventricular tachycardia. ment at a single center, and limited number of patients and narrow patient selection, which prohibit generalization to a larger population. As such, this technique remains investigational. Availability of ECGI remains limited outside of select institutions, so further evaluation of the necessity or optimal patient selection for use of this modality will be important. A critical next step in evaluation of this technique will be execution of a multicenter trial to demonstrate scalability of this approach outside a single institution while refining best practices for safety and efficacy. This technique may be of particular global interest given the more ubiquitous availability of SBRT compared with catheter ablation labs and expertise. Close collaboration between radiation oncologists and cardiac electrophysiologists is paramount for this technique to minimize patient risk and achieve high levels of ablation accuracy. Similar collaborative workflow models currently exist between radiation oncology and neurosurgery for intracranial radiosurgery.
CONCLUSIONS
In conclusion, in patients with intractable VT, the use of Electrophysiology-guided noninvasive stereotactic cardiac radiotherapy was associated with a marked reduction in the burden of VT with reduced antiarrhythmic medication use and improved quality of life.
